Category stocks

Aligos Therapeutics GAAP EPS of -$0.14

Aligos Therapeutics press release (ALGS): Q2 GAAP EPS of -$0.14. Cash, cash equivalents and investments totaled $30.4 million as of June 30, 2026, compared with $77.8 million as of December 31, 2025 This excludes the $25M upfront payment received from Amoytop in Jul

Sabre GAAP EPS of -$0.09, Revenue of $712M

Sabre press release (SABR): Q2 GAAP EPS of -$0.09. - Revenue of $712M (+3.6% Y/Y). - Operating income was $93M, up 4% Y/Y. ⢠Net loss attributable to common stockholders was $36M. ⢠Adjusted EBITDA was $143M, up 21% Y/Y. ⢠Normalized Adjusted EBITDA was $151M, up 19% Y/Y. â¢...</strong

Diageo Sets Out $1bn Savings Plan

Diageo has outlined plans to extract $1bn in savings from the business over the next three years. In a statement ahead of a much-anticipated investor meeting later today (6 August) the Guinness and Johnnie Walker maker said it expected to achieve around $1bn in savings "fr